Our observation is supported by data regarding reduced NLRP3-inflammasome activation in PBMCs observed in CF subjects receiving LUM/IVA or TEZ/IVA via decreased Caspase-1 activity by 3 months of treatment (Jarosz-Griffiths et al., 2020) and by the facts that treatment with Orkambi® restored CFTR dependent chloride efflux (Favia et al., 2020), decreased IL-18 and TNF-α expression in PBMCs (Jarosz-Griffiths et al., 2020), and improved airway epithelial repair (Adam et al., 2018), while Symdeko® downregulated serum IL-1β level in CF subjects (Jarosz-Griffiths et al., 2020). This evidence concerns the gene CASP1 and cystic fibrosis.